Strides Arcolab has rallied 5% to Rs 629, its lifetime high market price, after the company said it has received approval from the USFDA for Vancomycin Hydrochloride Capsules, an antibacterial indicated to treat infections that include C. difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus.
“According to IMS health data, Vancomycin Hydrochloride Capsules had total US sales of $332 million for the twelve months ending February 12, with no prior generic products. It is immediately available in 125 mg and 250 mg dosage strengths," Strides Arcolab said in a filing to the stock exchanges.
The product will be launched immediately through Alvogen on a profit share basis, it added. A combined 221,351 shares have changed hands on the counter till noon trades on both the exchanges.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app